Core Viewpoint - Xencor (XNCR) shares have increased by 5.9% recently, with a mean price target of $35.42 suggesting a potential upside of 53.5% from the current price of $23.07 [1] Price Targets - The average price target consists of 12 estimates ranging from a low of $20 to a high of $60, with a standard deviation of $11.19, indicating variability among analysts [2] - The lowest estimate suggests a decline of 13.3%, while the highest indicates a potential upside of 160.1% [2] - A low standard deviation signifies a strong agreement among analysts regarding the stock's price movement [7] Analyst Sentiment - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [9] - Over the past 30 days, six earnings estimates for XNCR have been revised upward, leading to a 7.9% increase in the Zacks Consensus Estimate [10] - XNCR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [11] Caution on Price Targets - Solely relying on price targets for investment decisions may not be prudent, as they can often mislead investors [5][8] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [6]

From a technical perspective, Xencor, Inc. (XNCR) is looking like an interesting pick, as it just reached a key level of support. XNCR's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.There's a reason traders love a golden cross -- it's a technical chart pattern that can indicate a bullish breakout is on the horizon. This kind of crossover is formed when a stock's short-term moving average breaks above a longer-term movin ...

Xencor (XNCR) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to loss of $0.40 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 27.55%. A quarter ago, it was expected that this biotech developing antibodies for severe autoimmune/allergic diseases and cancer would post a loss of $0.85 per share when it actually produced a loss of $1.07, delivering a surprise ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________________________________________ FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |----------------------------------------------------------------------|--------------------------- ...

Exhibit 99.1 Xencor Reports Third Quarter 2024 Financial Results PASADENA, Calif-- Nov. 6, 2024-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the third quarter ended September 30, 2024 and provided a review of recent business and clinical-stage program updates. "In September, we provided updates across our clinical pipeline of XmAb® bispecific T-cell engage ...

Shares of Xencor (XNCR) have gained 7.9% over the past four weeks to close the last trading session at $21.01, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $35.33 indicates a potential upside of 68.2%.The average comprises 12 short-term price targets ranging from a low of $20 to a high of $60, with a standard deviation of $11.22. While the lowest estimate indicates a decline ...

Core Viewpoint - Xencor (XNCR) shares have shown a modest gain of 0.4% over the past month, closing at $21.13, with analysts suggesting a potential upside of 67.2% based on a mean price target of $35.33 [1] Price Targets and Analyst Consensus - The average price target for XNCR is derived from 12 short-term estimates, ranging from a low of $20 to a high of $60, with a standard deviation of $11.22, indicating variability in analyst predictions [2] - The lowest estimate suggests a decline of 5.4%, while the highest indicates an upside of 184%, highlighting the range of opinions among analysts [2] - A low standard deviation signifies strong agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [7] Earnings Estimates and Potential Upside - Analysts have shown increasing optimism about XNCR's earnings prospects, as evidenced by a trend of higher EPS estimates, which correlates with potential stock price increases [9] - Over the past 30 days, three earnings estimates have been revised upward, leading to a 1.4% increase in the Zacks Consensus Estimate for the current year [10] - XNCR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential for upside [11]

tomazl Xencor (NASDAQ:XNCR) is an important biotech to keep an eye on, because it has a lot of upcoming catalysts within a 1-year period for investors to look forward to. One of which would be its lead program using vudalimab, which is an anti-PD-1 and anti-CTLA-4 inhibitor in development for the treatment of patients with metastatic castration-resistant prostate cancer in an ongoing phase 2 study. It is expected that monotherapy and combination dose cohorts' data targeting this specific patient population ...

Xencor (XNCR) shares rallied 10.5% in the last trading session to close at $21.13. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 19.8% gain over the past four weeks. This jump in share price came after the company announced that it was floating a secondary issue of common stock, along with pre-funded warrants, to raise nearly $175 million in gross proceeds. Management intends to issue more than 6.6 million ...

Financial Performance - Revenues for Q1 2024 were $12.8 million, a decrease of 32.4% compared to $19.0 million in Q1 2023[7] - Net loss for Q1 2024 was $68.0 million, or $(1.11) per share, compared to a net loss of $60.8 million, or $(1.02) per share, in Q1 2023[11] - Total operating expenses for Q1 2024 were $70.7 million, compared to $79.7 million in Q1 2023, reflecting a decrease of 11.3%[20] Research and Development - Research and development expenses for Q1 2024 were $56.9 million, down 13.2% from $65.6 million in Q1 2023[8] - The first patient was dosed in the Phase 1 study of XmAb541, targeting CLDN6-positive tumors, including advanced ovarian cancer[4] - A single dose of an investigational antibody with Xtend™ showed up to 77% effectiveness in preventing malaria in children[4] Cash and Assets - Cash, cash equivalents, and marketable debt securities totaled $646.7 million as of March 31, 2024, down from $697.4 million on December 31, 2023[6] - Total assets as of March 31, 2024, were $884.3 million, down from $952.7 million on December 31, 2023[18] - Xencor expects to end 2024 with between $475 million and $525 million in cash and equivalents, funding operations into 2027[5] Product Approvals - Ultomiris, incorporating Xencor's Xtend™ technology, was approved in the U.S. for treating adults with NMOSD[4]